Cervical cancer continues to be a leading cause of mortality worldwide. The incidence and mortality associated with invasive cervical cancer have declined significantly in developed countries due to widespread availability of screening with the Papanicolaou (Pap) test. However, the incidence and prevalence of non-invasive cervical intraepithelial neoplasms and genital warts related to oncogenic and nononcogenic strains of human papilloma viruses (HPV) have remained relatively stable. Recent advances in molecular diagnostics have resulted in improved characterization of various HPV types and have led to changes in terminology of Pap test findings. Changes in nomenclature may lead to confusion among primary care providers regarding how best to further evaluate abnormal cytological results. This article provides a concise overview of the approach to the treatment of genital warts and management of abnormal cervical cytology based on guidelines from the American Society of Colposcopy and Cervical Pathology. It also reviews advances in HPV vaccine development and the new recombinant vaccine recently approved for use in the United States. 
deaths among females worldwide, with an estimated 5,000,000 cases occurring annually and a 50% case fatality rate. 1 Currently, cervical cancer is the sixth most common cancer among women in the United States and ranks 13th among cancer-related deaths. 2 It is estimated that in the United States in the year 2007, 11,150 new cases of cervical cancer will be identified and 3,670 deaths will be attributed to this disease. 2, 3 Over the last 50 years, the incidence and mortality of invasive cervical cancer in the United States and in other developed countries has declined by nearly 70% due to the widespread use of cytological screening with the Papanicolaou (Pap) test resulting in the early detection and treatment of abnormal cervical cytology and intraepithelial neoplasia. 4 Over the past several years, screening recommendations have become available from various organizations, and screening guidelines in most primary care practices in this country are based on these recommendations. [5] [6] [7] Epidemiology of HPV Infection Cervical cancer is strongly associated with human papillomavirus (HPV) infection, a common sexuallytransmitted disease, and develops as a result of persistent infection with so-called high-risk or oncogenic types of HPV. 8, 9 Data from the 2003-2004 National Health and Nutrition Examination Survey found a 26.8% overall prevalence of HPV infection in self-collected vaginal samples from women 14 to 59 years old in the United States. 10 Epidemiological studies have shown that acquisition of HPV infection occurs within 1 to 2 years of onset of sexual activity in adolescent females and, in this group, the prevalence of HPV by polymerase chain reaction (PCR) can be as high as 64%. 11 In general, the prevalence of HPV infection is inversely related to age and increases with the number of sexual partners. Peak incidence of infection occurs in women aged 15 to 25 years. [12] [13] [14] [15] There may be a smaller peak in women over the age of 65 years. 16 One British study showed an increase in acquisition of the infection among HPV-negative women older than 51 years of age. 17 The prevalence of HPV infections is thought to be lower in men than in women, but one study of 18 to 70-yearold men attending a sexually-transmitted disease clinic found a 28.2% prevalence of HPV infection. 18 Another study found that 20% of uncircumcised and 5.5% of circumcised sexually active men had penile HPV by PCR. 19 HPV is also the causative organism in genital warts, which are prevalent in individuals who are immunosuppressed. Both genital warts and cervical cancer can be more severe and resistant to treatment in people infected with the human immunodeficiency virus (HIV). 20 As a result of the HIV epidemic, there has been a concomitant increase in the incidence of anal squamous cell carcinoma and anal carcinoma in situ, two conditions thought to be associated with persistent HPV infection. 21 
Viral Genotypes
HPV is a DNA virus belonging to the papovavirus family. There are over 100 subtypes of HPV based on differences in DNA sequences. Approximately 40 subtypes are associated with genital tract infection. These are divided into low-risk types (e.g., HPV 6 and 11), which are most commonly found in patients with condyloma acuminatum (i.e., genital warts) and high-risk types (e.g., HPV 16 and 18) associated with approximately 70% of invasive cervical cancers and over 90% of high-grade intraepithelial lesions. 4 Other high-risk types include HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. Infection with multiple HPV types can also occur, especially in individuals with visible genital warts.
HPV cannot be cultured in vitro. However, HPV infections with the more common high-risk types can be detected by DNA amplification methods such as PCR or the hybrid capture assay. 22, 23 Most PCR techniques are not standardized or validated and may only detect a few of the high-risk HPV types. The Digene Hybrid Capture 2 (HC2) is the only Food and Drug Administration-approved DNA test. HC2 is a signal-amplified, nucleic acid test that provides standardized, objective results for detecting 13 HPV DNA types associated with cervical cancer (i.e., HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and five low-risk types associated with genital warts (i.e., HPV 6, 11, 42, 43 and 44) . The test has been validated and has a sensitivity of >96% for detection of high-grade cervical intraepithelial neoplasm or cancer, when used in conjunction with cytology. 24 
Genital Warts
Approximately 30% of all genital HPV infections are clinically recognizable as anogenital warts. These painless, fleshy lesions have a predilection for moist, warm surfaces. The diagnosis is easily made based on direct visual inspection. 4, 25, 26 Genital warts are described as acuminate, papular or macular lesions. The presence of visible lesions in association with oncogenic types of HPV resulting in carcinoma in situ is sometimes referred to as Bowen's disease, while the presence of giant condylomata associated with nononcogenic types of HPV is referred to as a BuschkeLowenstein tumor. 4 The most common sites for genital warts in female patients are the ectocervix, labia, vagina, perineum and perianal area. The presence of intra-anal warts should raise the suspicion of receptive anal intercourse, and such patients should undergo cytological testing of cells from the anorectal zone, a digital rectal exam and direct visualization via anoscopy or sigmoidoscopy if the anal Pap test reveals cytological abnormalities. 21 Genital wart lesions generally start as small papules, which may then enlarge and coalesce via direct autoinoculation. They may occasionally grow to become very large masses, which can become secondarily infected, bleed or cause pain from direct pressure. The diagnosis of genital warts can be confirmed, if necessary, by biopsy. Indications for biopsy include an unclear diagnosis, non-response to or worsening during therapy, an immunocompromised patient or an ulcerated, fixed or pigmented lesion. There is no indication for HPV molecular testing, such as PCR or hybrid capture assay, for the diagnosis of genital warts. 25 There is no cure for HPV infection, and it should be emphasized to patients that they still are able to transmit the virus even in the absence of visible warts. There is no requirement for partner notification or treatment for genital warts. Additionally, genital warts and subclinical HPV infection may also occur in homosexual women who should be subjected to the same screening guidelines as their heterosexual counterparts. Thus, HPV infection may be acquired through non-penetrating intercourse. Barrier contraception, although important, does not provide complete protection, because oftentimes lesions are located on the vulva, labia and perineum. In spite of the lack of a specific cure, HPV colonization can be reversed (including pre-invasive neoplasia) by normal immune processes.
The goal of treatment of genital warts is eradication of visible and/or symptomatic warts. Treatment may be patient-or provider-administered, with the choice of treatment influenced by patient preference, provider experience, cost and convenience of treatment, anatomic location and extent of the warts. The presence of cervical and intra-anal warts is an indication for specialist referral. 25, 27 Prior to treatment, women with cervical warts who have not received a recent Pap test must have one in order to exclude any abnormal cytological findings that may require further evaluation, such as gynecological referral for colposcopy.
Treatment options are highlighted in table 1. 25 If lesions have not improved after three provider-administered treatments or have not cleared completely after six treatments, consideration should be given to switching to a different treatment modality. For patients who failed initial therapy, a combination therapy with two different regimens may also be considered. However, this is not always successful and may be associated with an increased frequency of side effects.
Side effects of treatment are minimal and are typically related to pain and irritation at the application site of the lesion. vulvodynia. The risk of recurrence after treatment is high, particularly within the first 3 months.
In pregnant women, treatment options are limited to cryotherapy, trichloroacetic acid treatment, and surgical removal. Podophyllin-derived therapies and imiquimod are specifically contraindicated in pregnancy. 25 Genital warts are not an indication for cesarean section, unless there is obstruction of the birth canal.
Screening for Cervical Cancer
The goal of screening with a Pap test is to identify and treat any high grade squamous intraepithelial lesions (HSIL), which are associated with an increased risk of invasive cervical cancer. Most practice guidelines recommend commencement of screening at 21 years of age or within 3 years of onset of sexual activity, whichever comes first. [5] [6] [7] In women with HIV/AIDS, the Pap test should be obtained twice during the first year after diagnosis of HIV infection and, if the results are normal, annually thereafter. 23, 27 Some experts also recommend anal Pap tests annually for HIV-positive and every 2 to 3 years for HIV-negative bisexual and homosexual men. 21 Screening should occur annually with the conventional Pap test or every 2 years with the liquid-based test (ThinPrep System, Cytyc, Marlborough, MA) until the age of 30, following which screening can be every 2 to 3 years if the woman is not immunosuppressed and has had 3 consecutive normal Pap tests. Women aged 65 to 70 years or older who have had 3 consecutive normal Pap tests in the preceding 10 years need not continue screening. 5 Women who have undergone total hysterectomy for a documented benign reason do not require further screening with a Pap test. This does not include women who have had a subtotal hysterectomy with the cervix still present, as they are still subject to the screening guidelines.
Cytology, however, is not the recommended method of screening women suspected of having endometrial or endocervical abnormalities and is only 50% to 75% effective in identifying glandular neoplasm. These guidelines also do not apply to immunosuppressed or immunocompromised women or to those exposed to diethylstilbestrol in utero who should continue receiving annual Pap tests irrespective of age, method of obtaining the Pap or presence of hysterectomy. In addition, these guidelines do not apply to women who have been treated for cervical cancer and who require ongoing surveillance.
The guidelines also recommend using the liquid-based Pap test because of its decreased likelihood of unsatisfactory samples, while still maintaining equivalent sensitivity as compared to the conventional Pap test. 28, 29 Liquid-based Pap tests provide the added value and convenience of reflex testing for HPV following an abnormal cytological result. 30, 31 For endocervical neoplasia and atypical glandular cells (AGC), liquid-based testing is superior to a conventional "smear" technique as it increases the specificity. 32
Classification of Cervical Cytology
The criteria for describing cytological abnormalities identified on the Pap test are based on the Bethesda System of classification and were modified in 2001. 33 This change incorporated the relatively new technologies of the liquidbased Pap test and genetic testing for HPV DNA. This cytological terminology may introduce confusion regarding the appropriate triage and management decisions in patients with abnormal test results.
The 2001 Bethesda system of classification of Pap tests is a revised method of uniform laboratory reporting of cervical cytology results. It consists of five parts of which at least three are usually required. The first component of the report is a comment regarding the specimen's adequacy for interpretation which is stated as either satisfactory or unsatisfactory. If it is the latter, then further clarification as to whether the specimen was rejected or analyzed is provided. The second component is not required and is a general categorization of the specimen as either positive or negative for epithelial abnormality. The third and most important part of the Bethesda system is the interpretation of the result, which consists of an expanded description based on the type of epithelial cell abnormality (e.g., squamous vs. glandular), extent of atypical cell transformation and the presence of organisms or endometrial cells. If the laboratory utilizing the system has an automated review system or performs additional testing, such as DNA testing, this information must also be reported and is the fourth component of the Bethesda system. Last is the comments section which is also optional.
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Patient-administered
• 0.5% podofilox solution applied to visible warts twice daily for 3 days followed by 4 days of no treatment, repeated up to four cycles • 5% imiquimod (Aldara) cream applied at bedtime for 6 to 10 hours 3 times a week for up to 16 weeks Provider-administered
• Cryotherapy with liquid nitrogen applied every 1 to 2 weeks • 10% to 25% podophyllin in a compound tincture of benzoic applied weekly • 80% to 90% Trichloroacetic or Bichloroacetic acid applied to lesions and repeated weekly • Surgical removal by curettage, shave excision, laser or electro surgery • Intralesional interferon injection Comments usually take the form of a suggestion and may reference practice guidelines for further management of the patient as clinically warranted.
Management of Abnormal Cervical Cytological Results
Glandular cell abnormalities described in the revised Bethesda system include the following categories: (1) AGC, LSIL Approximately 15% to 30% of women with LSIL on cytology will have high-grade CIN on histology. 38 The remainder will either have no lesion or have CIN-1 on biopsy. In the past, a conservative approach of monitoring women with LSIL by repeat cytology was advocated because of the tendency for these lesions to spontaneously regress. However, due to concerns related to the high incidence of patients lost to follow-up, the ASCCP now recommends that all women with LSIL be referred for colposcopy (table 2) . This allows for early detection of women with significant disease and alleviates the concern that patients will be lost to follow-up. Adolescents and postmenopausal women deemed as reliable for follow-up should still be managed per ASC-US guidelines.
If no CIN is detected on biopsy, repeat cytology at 6-month and 12-month intervals or DNA testing for high risk HPV types at 12 months is recommended. If either of these tests is negative, routine screening is recommended. If cytology detects atypical squamous cells, ASC-H or HSIL or if HPV DNA is positive, patients should be referred for colposcopy. If the biopsy is positive for CIN, management should follow the ASCCP guidelines. 37 HSIL HSIL is reported to account for <1% of all cytologic abnormalities identified. Approximately 75% of women with HSIL will have CIN grade 2/3 on biopsy, and up to 2% will have invasive cancer. 37, 38 The ASCCP recommends immediate colposcopy with endocervical assessment. For non-pregnant females, immediate excision is another option. 37 When to Refer to a Specialist All patients with squamous cell carcinoma in situ or any glandular cell atypia, as well as those over 40 years of age with the presence of endometrial cells on cytologic screening should be referred to a specialist for colposcopy, endocervical sampling and/or endometrial sampling, as appropriate. 36, 37 Any patient with atypical squamous cells on repeat cytologic testing and women with high-grade lesions should also be referred for colposcopy. Decisions regarding referral for LSIL can be appropriately individualized depending upon the reliability of follow-up for each individual patient. With respect to genital warts, the presence of endocervical or rectal warts is an indication for specialist referral. 25 particles for specific HPV genotypes at protecting against the development of infection. 39, 40 There are two vaccines which have recently been developed, Gardasil (Merck, Whitehouse Station, NJ) and Cervarix (GlaxoSmithKline, Research Triangle Park, NC).
HPV Vaccine
Gardasil is a quadrivalent recombinant vaccine containing L1 viral-like particles for HPV types 6, 11, 16 and 18. 41 In a phase III prospective, randomized, double-blind, placebocontrolled study (FUTURE II), over 12,000 women aged 16 to 26 years from 13 countries were randomized to receive either Gardasil or a placebo vaccine. 42 The vaccine was administered in a three-dose regimen given at 0, 2 and 6-month intervals. The primary outcome was the incidence of CIN-2/3 or AIS. The women were followed for up to 17 months after completion of the vaccine regimen. 34, 35 Gardasil was evaluated and approved within a 6-month period by the Food and Drug Administration through a priority review process (which is only available for products having the potential to provide significant health benefits). 43 According to the new ACIP guidelines, Gardasil will now be routinely administered as part of the childhood immunization schedule to girls at age 11 or 12 years, with the allowance for the vaccination as early as 9 years of age, if necessary. 44 The vaccine should be administered prior to the onset of sexual activity and subsequent exposure to the virus, as this is when it provides maximum benefit. However, the ACIP also recommends immediate vaccination of all girls and women 13 to 26 years of age, irrespective of current sexual practice or presence of HPV infection, because they can still derive some benefit from the vaccine. Gardasil is administered as a 0.5 cc intramuscular injection at 0, 2 and 6 month intervals, and preliminary results show efficacy up to 4.5 years. At present, Gardasil is contraindicated in pregnant and lactating women. The vaccine does not take the place of routine screening for cervical cancer or treatment of symptomatic genital warts. It is unclear what impact, if any, Gardasil will have on clearance of an established infection or intraepithelial neoplasia, and research is ongoing. For now the vaccine is only licensed for use prophylactically.
Conclusion
HPV infection is a common, treatable, and preventable infection in women. Early detection and appropriate management of pre-invasive lesions are crucial for preventing invasive squamous malignancies, particularly as mounting evidence suggests that such tumors in the rectum, penis, vagina and vulva may also be related to persistent HPV infection. [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] The introduction of the liquid-based Pap test and molecular diagnostics techniques has provided new approaches to the management of cytological abnormalities. The HPV vaccine is expected to further decrease the acquisition of HPV infections, the precursor of invasive malignancies, as well as the morbidity associated with genital warts. However, until more information regarding the vaccine's long-term efficacy becomes available, the Pap test will continue to be an important tool in the prevention of invasive cervical cancer.
